Skip to main content
. 2009 Jun;5(6):435–442.

Figure 4.

Figure 4

Symptom relapse among subjects who initially fail with no prevention and proceed to erythromycin or tegaserod (A). Symptom relapse among subjects who relapse on erythromycin as a prevention strategy and subsequently switch to tegaserod (B).